-
Kenya's economy faces climate change risks: World Bank
-
Philips profits double in first quarter
-
100 years on Earth: Iconic naturalist Attenborough marks century
-
Boycott-hit 70th Eurovision celebrated under high security
-
Teen shooter kills two at Brazil school
-
Fresh UAE attacks blamed on Iran draw new reality in the Gulf
-
US declares Iran offensive over, warns force remains an option
-
Mexican BTS fans go wild as concerts grow near
-
Europe's first commercial robotaxi service rolls out in Croatia
-
Suspected hantavirus cases to be evacuated from cruise ship
-
Rolling Stones announce July 10 release of new album 'Foreign Tongues'
-
EU urges US to stick to tariff deal terms
-
Stocks rise, oil falls as traders eye earnings, US-Iran ceasefire
-
Colombian mine explosion kills nine
-
Vodafone to take full ownership of UK mobile operator
-
US trade gap widens in March as AI spending boosts imports
-
Pyongyang calling: North Korea shows off own-brand phones
-
Iran warns 'not even started' in Hormuz
-
Yoko says oh no to 'John Lemon' beer
-
Stocks sink amid fears over US-Iran ceasefire
-
Premier League losses soar for clubs locked in 'arms race'
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Pulitzers honor damning coverage of Trump and his policies
-
Digi Power X Signs AI Colocation Agreement with Leading AI Compute Company for 40 MW Data Center in Columbiana, Alabama
-
US-Iran ceasefire on brink as UAE reports attacks
-
OpenAI co-founder under fire in Musk trial over $30 bn stake
-
Amazon to ship stuff for any business, not just its own merchants
-
Passengers stranded on cruise off Cape Verde following suspected virus deaths
-
What is hantavirus, and can it spread between humans?
-
Two dead as car ploughs into crowd in Germany's Leipzig
-
Demi Moore joins Cannes Festival jury
-
Two dead after car ploughs into people in Germany's Leipzig: mayor
-
Stars set for Met Gala, fashion's biggest night
-
France launches one-euro university meals for all students
-
Mysterious world beyond Pluto may have an atmosphere: astronomers
-
Energy crisis fuels calls to cut methane emissions
-
Hantavirus: spread by rodents, potentially fatal, with no specific cure
-
Musk vs OpenAI trial enters second week
-
Japan PM says oil crisis has 'enormous impact' in Asia-Pacific
-
Seoul, Taipei hit records as Asian stocks track Wall St tech rally
-
Boeing faces civil trial over 737 MAX crash
-
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business
-
Three die on Atlantic cruise ship from suspected hantavirus: WHO
-
Two die in 'respiratory illness' outbreak on Atlantic cruise ship
-
More Nepalis drive electric, evading global fuel shocks
-
Latecomer Japan eyes slice of rising global defence spending
-
German fertiliser makers and farmers struggle with Iran war fallout
-
OPEC+ to make first post-UAE production decision
-
Massive crowds fill Rio's Copacabana beach for Shakira concert
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
U.Ndiaye--CPN